Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement

A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.